Haleon Share Discussion Threads

[zho] 02/5/2024 08:12

Barclays raise HLN target to 400p (383p) - Overweight

[philanderer] 18/4/2024 11:25

HSBC starts Haleon with 'buy' - price target 370 pence

[ygor705] 28/3/2024 09:59

Sp showing good strength here in a period when it could well have gone the other way. Next test will probably come when the lock up periods arising from the recent placements finish.

[patientcapital] 19/3/2024 11:39

It is positive that the offer was upsized (ghastly word) by 160m shares one assumes due to institutional demand.

[alphorn] 19/3/2024 10:11

Not forgetting that a takeover is made easier if a large holder agrees to sell in advance to an acquirer. HLN IMO will get acquired at some point.

[simon8] 19/3/2024 10:06

Agree on the divi, not good, GSK still have a rump holding too to offload so more of the same to come from them. I had only kept these post the demerger on the hope that they would be taken over, but guessing that is unlikely or way out in the future once both Pfizer and GSK have done selling... until they are both clear I think the share price will languish in in the current trading range.

[alphorn] 18/3/2024 11:49

Pfizer to cut stake in HLN - see above.

[anhar] 29/2/2024 11:36

Final divi 4.2p

xd 14 March, pd 16 May

Total for year 6.0p

Trailing yield at 330p 1.8% which is low but I'm retaining the shares, received from the GSK demerger, as an income investor.

[patientcapital] 29/2/2024 08:29

Good figures. Debt coming down nicely.

[grahamburn] 25/1/2024 10:34

But reduces debt which is other side of the coin - and probably the shinier side

[jonnybig] 25/1/2024 07:52

Problem with disposals is that they're a short term sticking plaster losing a long term income stream.

[simon8] 25/1/2024 07:44

Bon voyage Chapstick, looks like a good deal, cash, pay down debt and a passive forward interest. Let's hope we see an uptick in the share price, we need it!

[pdosullivan] 17/1/2024 23:11

Another very welcome placing by GSK, which has now sold down two thirds of the shares it originally held post IPO. Given the cash HLN is throwing off and reports that it might sell one of its brands for up to USD800m I wonder if the company might bid GSK for some or all of its remaining stock later this year.

[zho] 17/1/2024 10:55

GSK plc (LSE/NYSE: GSK) today announced that, further to its announcement on 16 January 2024, GSK has agreed to sell 300m ordinary shares in Haleon plc ("Haleon") at a price of 326 pence per share (the "Placing Shares"), raising gross proceeds of approximately GBP978m (the "Placing").

Following settlement of the Placing, GSK will hold approximately 385m ordinary shares in Haleon, representing approximately 4.2% of the issued share capital of Haleon.

[patientcapital] 19/12/2023 15:55

Decent director purchase.

[anhar] 15/12/2023 13:45

Trailing yield is actually 1.3%. This is based on last 12m divis total 4.2p (22 final of 2.4p plus 23 interim 1.8p) on the share price of 319p. The 23 forecast is for 5.5p making a forward yield of 1.7%.

Still very low though.

I hold HLN acquired via the GSK demerger and what may be supporting the price, if you think there is a reason other than the normal random walk of share prices, is bid hopes, as you suggest. Everyone thinks that, making it less likely!

[alphorn] 14/12/2023 18:57

Still don't understand what is holding up this share price P/e close to 20 and a yield below 1% makes little sense for this sector.

I expect the company to be taken out but at what price?

Patient, you have holdings here. Do you have any answers; it just seems unsupportable?

[patientcapital] 11/12/2023 11:56

Haleon seen growing after wobbly start -- Market TalkSource: MF Dow Jones (English)Original article published on Dow Jones English Newswire, translated by editorial staff Il Sole 24 Ore Radiocor.(Il Sole 24 Ore Radiocor Plus) - Milan, Dec 11 - Haleon is expected to start seeing a smoother growth path after facing several challenges since its IPO, Jefferies analysts write in a note after updating their rating on the stock to buy from hold.The 2025 results of the consumer-healthcare sector should at least be in line with expectations, thanks to better and less volatile sales growth, according to Jefferies analysts.Haleon's strategy - which has not yet been employed due to pandemic disruptions and soaring production factor costs - appears to be rekindling with the group's increased engagement in new combined category exposures, they add."Haleon is our favourite name in the consumer health industry, with more predictable and consistent results in both revenue and earnings," they add.Shares are up 0.5% to 326.3 pence.([e-mail])(END) Dow Jones NewswiresDecember 11, 2023 03:50 AM ET (08:50 GMT)Copyright (c) 2023 Dow Jones-Radiocour

[duckplaudits] 02/11/2023 16:12

May I ask whether anyone thinks this is worth buying or even holding excluding the acknowledged defensive qualities given the valuations and share overhang? aND IF SO WHY.
All I could see from the update was that profits were hit by a reversal in currency to a headwind rather than a following one resulting in poorish revenues and a small drop in reported profits for Q3 (rather than adjusted ones)..I am aware that GSK has sold some stock but Pfizer still has a massive position while some more conservative US funds or ETFs have been buying presumably because it is big ($30bn) and steady. But Haleon also has pretty big debts at a time of higher rates though I am sure most are term rather than imminent.

[anhar] 02/11/2023 13:21

I see the update as pretty good.

Revenue for the 9 months is £8,536m against £8,080m.

Diluted eps is 11.3p against 9.3p.

...Our FY guidance remains unchanged and we expect to deliver strong growth in both organic revenue and adjusted operating profit constant currency...

[csalvage] 02/11/2023 11:10

I thought this looked like a good update, what's not to like about it.

[alphorn] 10/10/2023 11:59

Re. today's RNS - What is the difference between Scottish and English limited partnerships? Under the Partnership Act 1890 Scottish firms are legally separate to their partners. This means that Scottish limited partnerships (SLPs), unlike those based in England and Wales or Northern Ireland, have 'legal personality', allowing them to hold assets and enter into contracts in their own right.

........I did not know that.